Advanced Cell Therapy Development Platform

PARTNERSHIPS

Advancing Science & Manufacture of Cellular Therapeutics

A strategic publicnprivate initiative integrating cell biology, bioprocess development, pharmaceutical quality systems, translational research and commercial-scale implementation

The Thailand Institute of Scientific and Technological Research (TISTR) and Vega Wellness are advancing an integrated platform for the development of next-generation cellular therapeutics, with a particular focus on allogeneic umbilical cord-derived mesenchymal stromal/stem cells (UC-MSCs).


From biological starting material and cell expansion to analytical characterization, quality control, preclinical evaluation and translational development, the initiative is designed to support the progression of cellular technologies toward reproducible, quality-controlled and clinically relevant applications.

An Integrated Platform for Advanced Therapeutics

Advanced cell therapies require more than the ability to culture cells.

They require an integrated development system capable of controlling biological variability, manufacturing processes, analytical methods, product quality and translational risk.


The TISTR and Vega Wellness initiative brings these disciplines together within a unified scientific and manufacturing framework


CELL SOURCE & BANKING

Controlled biological starting materials, cell-bank development and traceability

PROCESS DEVELOPMENT

Standardized isolation, expansion, harvesting and formulation methodologies

ANALYTICAL SCIENCE

Characterization of cellular identity, purity, viability, stability and biological function

MANUFACTURING & QUALITY

GMP-oriented manufacturing systems supported by pharmaceutical quality and risk-management principles

Students attentively participate in a classroom session.

PRECLINICAL DEVELOPMENT

Scientific evaluation of safety, biological activity and translational potential

CLINICAL TRANSLATION

Structured progression toward appropriately governed clinical investigation and real-world application

Building the Infrastructure for Advanced Cell Manufacturing

Pharmaceutical-Level Control for Living Biological Products

Cellular therapeutics present manufacturing challenges fundamentally different from conventional small-molecule medicines.

Cell phenotype, viability, biological activity and product consistency may be influenced by starting material, culture conditions, passage number, processing conditions, environmental controls, transport and analytical methodology.


The manufacturing program is therefore being developed around a lifecycle-based quality approach in which critical processes are controlled from biological source through final product.


Core areas include:

PIC/S GMP-Oriented Infrastructure

Manufacturing systems designed around internationally recognized Good Manufacturing Practice principles

Aseptic Processing

Controlled processing environments and contamination-control strategies suitable for sensitive biological products

Process Control

Definition and monitoring of critical manufacturing parameters affecting product quality

Batch Traceability

Documented chain of identity, chain of custody and manufacturing history

Quality Control

Analytical testing and predefined specifications supporting product consistency and safety

Cell Science Driven by Characterization

GenerateUnderstanding the Product Beyond Cell Countexcitement

For advanced cellular products, cell number alone is not an adequate definition of product quality.

A scientifically meaningful cellular product requires characterization of the biological attributes that define its identity, integrity and functional profile.

Development programs may therefore evaluate parameters including:


  • Identity and phenotype
  • Viability
  • Purity
  • Cell morphology
  • Population consistency
  • Microbiological safety
  • Sterility
  • Mycoplasma
  • Endotoxin
  • Genetic or chromosomal stability
  • Senescence-associated characteristics
  • Functional activity
  • Potency-associated biological responses


These parameters contribute to the establishment of Critical Quality Attributes (CQAs) that can be monitored throughout process development and manufacturing.

TRANSLATIONAL RESEARCH

Scientists in lab coats and masks analyzing data on a computer.

From Biological Discovery to Translational Evidence

Cellular technologies should progress through structured scientific development rather than moving directly from laboratory observations to clinical claims.

Our translational framework follows a staged development

DISCOVERY

Understanding cellular biology and potential mechanisms

CHARACTERIZATION

Defining relevant biological and quality attributes

PROCESS DEVELOPMENT

Establishing controlled and reproducible manufacturing methods

PRECLINICAL EVALUATION

Assessing safety and biological activity in appropriate experimental models

CONTROLLED MANUFACTURING

Producing cellular material under defined quality systems

CLINICAL INVESTIGATION

Evaluating safety and clinical outcomes through appropriately designed research

SCALE-UP & TRANSLATION

Preparing validated processes for broader scientific and commercial implementation

COLLABORATION

Science Advances Through Collaboration

The initiative is designed as a multidisciplinary platform connecting:


  • Government Research
  • Academic Institutions
  • Hospitals & Clinical Researchers
  • Biotechnology Companies
  •  Pharmaceutical Researcher
  •  Analytical Laboratories
  •  International Scientific Institutions

Collaborative programs may include:

  • Cell-therapy development
  • Translational research
  • Preclinical studies
  • Analytical method development
  • Technology transfer
  • Process optimization
  • Clinical research collaboration
  • Scientific training
  • International knowledge exchange

SCIENTIFIC EXCHANGE

Advancing the Regional Cell-Therapy Ecosystem

TISTR’s scientific activities extend beyond laboratory development to international knowledge exchange across cell therapy, extracellular vesicles, advanced biological manufacturing and translational medicine.


Scientific conferences, workshops and professional education create a forum where researchers, clinicians, manufacturers, regulators and biotechnology organizations can examine emerging science and the practical challenges associated with translating advanced therapeutics.

Key Areas

Scientific Conferences

International scientific exchange across regenerative medicine and advanced biological therapeutics

Technical Training

Cell handling, manufacturing principles, quality systems and analytical methodologies

Translational Workshops

Connecting laboratory science with preclinical and clinical development.

Regulatory Science

Supporting informed discussion of evolving standards for advanced therapies

GOVERNANCE

Scientific Rigor at Every Stage

Responsible development of cellular therapeutics requires more than innovation. It requires governance.


The initiative integrates scientific oversight, pharmaceutical quality principles, ethical research practice, data integrity and translational risk management throughout the product-development lifecycle.


Our Development Principles

Scientific Integrity

 Decisions guided by evidence and reproducible data

Quality by Design

Product quality designed into the process rather than tested only at completion

Patient Safety

Risk assessment incorporated throughout development

Traceability

Transparent documentation from source material through manufacturing and application

Regulatory Readiness

Development strategies designed with evolving advanced-therapy requirements in mind

Responsible Translation

Clear distinction between research findings, investigational applications and established clinical evidence.

Building the Infrastructure Behind Tomorrow’s Biological Medicines

The future of regenerative medicine will depend not simply on discovering new cellular technologies.


It will depend on our ability to manufacture, characterize, test and evaluate them with the same scientific discipline expected of modern pharmaceutical products.

Through the integration of national research capability, advanced biotechnology infrastructure and commercial execution, TISTR and Vega Wellness aim to contribute to the development of a sustainable advanced-therapy ecosystem in Thailand.